Camp4 Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A proprietary ASO platform is advancing toward clinical trials for SYNGAP1-related disorder, aiming to be first-in-class for this rare epilepsy. Preclinical data show dose-dependent restoration of protein and function, with a pediatric-focused phase I/II trial planned for later this year.
-
The discussion highlighted a CNS-focused platform using oligonucleotides to upregulate gene expression, with the lead program CMP-002 targeting SYNGAP1-related disorders. The phase I/II trial will begin in severe pediatric patients this year, focusing on seizure reduction and other meaningful endpoints, with strong financial runway into 2028.
-
The platform uses ASOs to upregulate gene expression by targeting regulatory RNAs, with a focus on haploinsufficient CNS diseases like SYNGAP1. Clinical development is informed by robust preclinical data, natural history studies, and regulatory support, while partnerships like GSK expand reach to other indications.
-
CMP-002 is advancing as a first-in-class disease-modifying therapy for SYNGAP1 disorders, with robust preclinical data and a global phase I-II trial planned for later this year. The proprietary RAP platform underpins a growing pipeline, supported by strategic partnerships and strong financials through 2027.
Fiscal Year 2025
-
The company is advancing a platform targeting regulatory RNAs to upregulate gene expression, with a lead program in SYNGAP1-related disorders showing strong preclinical results and clinical entry expected next year. Financially, it is well-funded into 2027 and aims to expand its CNS pipeline.
-
Panelists highlighted advances in non-coding RNA research, with platforms enabling precise target identification and therapeutic development for diseases like CNS disorders and cardiac fibrosis. Strategic focus, strong partnerships, and rigorous validation are driving progress, despite challenges in target validation and drug design.
-
The conference highlighted a platform using antisense oligonucleotides to upregulate gene expression, with a lead program in urea cycle disorder advancing toward patient studies and a growing CNS pipeline. Strategic partnerships and efficient operations support rapid expansion and development.
-
The RAP Platform enables targeted upregulation of gene expression for diseases with protein deficiencies, with lead programs in urea cycle disorders and genetic epilepsy advancing in the clinic. Major clinical readouts and IND-enabling studies are expected in 2024–2025, supported by strong market opportunities and active business development.
-
The company is advancing a platform for upregulating gene expression using antisense oligonucleotides, with lead programs in urea cycle disorders, SYNGAP1 haploinsufficiency, and Parkinson’s disease. Key clinical readouts and regulatory milestones are expected this year, supported by strong preclinical data and strategic partnerships.
Fiscal Year 2024
-
The company is advancing a proprietary regRNA platform to upregulate gene expression for rare diseases, with lead program CMP-CPS-001 in phase I for urea cycle disorders and a growing CNS pipeline. Strategic partnerships and a strong cash position support expansion into new indications.